



*Handwritten signature*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Stefanic, M. F. et al ) Art Unit: 1614  
U.S. Appln. No. : 10/830,147 ) Examiner:  
Confirmation No. : 7845  
U.S. Filing Date : 04/22/2004  
Title of Invention : Combinations for the Treatment of Diseases Involving Cell Proliferation,  
Migration or Apoptosis of Myeloma Cells or Angiogenesis  
Attny. Docket No. : 1/1464

Mail Stop Amendment  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

January 31, 2006

TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Transmitted herewith concerning the subject application is an Information Disclosure Statement (Form 1449A and B) with copies of all non-US patent references cited therein. This is being submitted pursuant to 37 C.F.R. § 1.56 and before the mailing of a first Office Action on the merits, pursuant to 37 CFR § 1.97(b).

It should be noted that the references listed in the Information Disclosure Statement have been cited in the International Search Report (ISR) for PCT/EP2004/004363, which corresponds to the present US application. A copy of that ISR is enclosed herewith.

☒ 1.97(b). This Statement is being filed: i) within three (3) months of the filing date of a national application other than a continued prosecution application under 33 C.F.R. § 1.53 (d); ii) within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application; iii) before the mailing of a first Office action on the merits; or iv) before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. § 1.114.

☐ 1.97(c). This Statement is being filed after the time period specified in 37 C.F.R. § 1.97(b), but before the mailing date of: i) a final action under 37 C.F.R. § 1.113, ii) a notice of allowance under 37 C.F.R. § 1.311, or iii) an action that otherwise closes prosecution in the application. This Statement is being accompanied by:

☐ A statement as specified in 37 C.F.R. § 1.97(e) [see below]; or

☐ The fee set forth in 37 C.F.R. §1.17(p).

☐ The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.

☐ 1.97(d). This Statement is being filed after the period specified in 37 C.F.R. §1.97(c) but on or before payment of the issue fee. This Statement is accompanied by a statement as specified in 37 C.F.R. §1.97(e) [see below] and the fee set forth in 37 C.F.R. §1.17(p).

☐ 1.97(e).

☐ Each item of information contained in the instant information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of the instant information disclosure statement; or

☐ No item of information contained in the instant information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this certification after making reasonable inquiry, no item of information contained in the instant information disclosure statement was known to any individual designated in 37 C.F.R. §1.56(c) more than three (3) months prior to the filing of the instant information disclosure statement.

☐ The fee set forth in 37 C.F.R. §1.17(p).

☐ The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.

☐ 1.704(d). Each item of information contained in the accompanying information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, which communication was not received by any individual designated in section 1.56(c) more than thirty (30) days prior to the filing of the accompanying information disclosure statement.

☒ The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Respectfully submitted,



Anthony P. Bottino  
Attorney for Applicant(s)  
Reg. No. 41,629


Patent Department  
Boehringer Ingelheim Corp.  
900 Ridgebury Road, P.O. Box 368  
Ridgefield, CT 06877  
Tel: (203) 791-6764

Certificate of Mailing


I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop Amendment  
Commissioner For Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

on January 31, 2006.



Anthony P. Bottino, Reg. No. 41,629



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 3

**Complete if Known**

|                        |                           |
|------------------------|---------------------------|
| Application Number     | 10/830,147                |
| Filing Date            | 04/22/2004                |
| First Named Inventor   | Martin Friedrich STEFANIC |
| Art Unit               | 1614                      |
| Examiner Name          |                           |
| Attorney Docket Number | 1/1464US                  |

**U. S. PATENT DOCUMENTS**

| Examiner Initials* | Cite No. <sup>1</sup> | Document Number                          | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | Pages, Columns, Lines, Where<br>Relevant Passages or Relevant<br>Figures Appear |
|--------------------|-----------------------|--|--------------------------------|--|---|
|                    |                       | Number-Kind Code <sup>2</sup> (if known) |                                |  |   |
|                    |                       | US- 2003/0069299 A1                      | 04/10/2003                     | Walter, R. et al                                   |   |
|                    |                       | US- 6,306,874 B1                         | 10/23/2001                     | Fraley, M. E. et al                                |   |
|                    |                       | US- 2003/0119819 A1                      | 06/26/2003                     | Liang, C. et al                                    |   |
|                    |                       | US- 2003/0108545 A1                      | 06/12/2003                     | Rockwell, P. et al                                 |   |
|                    |                       | US- 2004/0176392 A1                      | 09/09/2004                     | Roth, G. J. et al                                  |   |
|                    |                       | US- 6,794,393 B1                         | 09/21/2004                     | Fraley, M. E. et al                                |   |
|                    |                       | US- 2004/0127453 A1                      | 07/01/2004                     | Lyons, J. et al                                    |   |
|                    |                       | US- 6,762,180 B1                         | 07/13/2004                     | Roth, G. J. et al                                  |   |
|                    |                       | US-                                      |                                |  |   |
|                    |                       | US-                                      |                                |  |   |
|                    |                       | US-                                      |                                |  |   |
|                    |                       | US-                                      |                                |  |   |
|                    |                       | US-                                      |                                |  |   |
|                    |                       | US-                                      |                                |  |   |
|                    |                       | US-                                      |                                |  |   |
|                    |                       | US-                                      |                                |  |   |
|                    |                       | US-                                      |                                |  |   |
|                    |                       | US-                                      |                                |  |   |

**FOREIGN PATENT DOCUMENTS**

| Examiner Initials* | Cite No. <sup>1</sup> | Foreign Patent Document   | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | Pages, Columns, Lines,<br>Where Relevant Passages<br>or Relevant Figures Appear | T <sup>6</sup> |
|--------------------|-----------------------|---|--------------------------------|--|---|----------------|
|                    |                       | Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known) |                                |  |   |                |
|                    |                       | WO 03 011837 A1   | 02/13/2003                     | Merck & Co., Inc.                                  |   |                |
|                    |                       | WO 03 022815 A1   | 03/20/2003                     | Liang, C.  |   |                |
|                    |                       | WO 02/070008 A1   | 09/12/2002                     | Imclone Systems, Inc.                              |   |                |
|                    |                       | DE 102 33 500 A1  | 02/19/2004                     | BI Pharma GmbH                                     |   |                |
|                    |                       | WO 01 32651 A1  | 05/10/2001                     | Astrazeneca AB                                     |   |                |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 3**Complete if Known**

|                        |                           |
|------------------------|---------------------------|
| Application Number     | 10/830,147                |
| Filing Date            | 04/22/2004                |
| First Named Inventor   | Martin Friedrich STEFANIC |
| Art Unit               | 1614                      |
| Examiner Name          |                           |
| Attorney Docket Number | 1/1464US                  |

**U. S. PATENT DOCUMENTS**

| Examiner Initials* | Cite No. <sup>1</sup> | Document Number                          | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | Pages, Columns, Lines, Where<br>Relevant Passages or Relevant<br>Figures Appear |
|--------------------|-----------------------|--|--------------------------------|--|---|
|                    |                       | Number-Kind Code <sup>2</sup> (if known) |                                |  |   |
|                    |                       | US-                                      |                                |  |   |
|                    |                       | US-                                      |                                |  |   |
|                    |                       | US-                                      |                                |  |   |
|                    |                       | US-                                      |                                |  |   |
|                    |                       | US-                                      |                                |  |   |
|                    |                       | US-                                      |                                |  |   |
|                    |                       | US-                                      |                                |  |   |
|                    |                       | US-                                      |                                |  |   |
|                    |                       | US-                                      |                                |  |   |
|                    |                       | US-                                      |                                |  |   |
|                    |                       | US-                                      |                                |  |   |
|                    |                       | US-                                      |                                |  |   |
|                    |                       | US-                                      |                                |  |   |
|                    |                       | US-                                      |                                |  |   |
|                    |                       | US-                                      |                                |  |   |
|                    |                       | US-                                      |                                |  |   |
|                    |                       | US-                                      |                                |  |   |
|                    |                       | US-                                      |                                |  |   |
|                    |                       | US-                                      |                                |  |   |
|                    |                       | US-                                      |                                |  |   |

**FOREIGN PATENT DOCUMENTS**

| Examiner Initials* | Cite No. <sup>1</sup> | Foreign Patent Document   | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | Pages, Columns, Lines,<br>Where Relevant Passages<br>or Relevant Figures Appear | T <sup>6</sup> |
|--------------------|-----------------------|---|--------------------------------|--|---|----------------|
|                    |                       | Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known) |                                |  |   |                |
|                    |                       | WO 03 065995 A2   | 08/14/2003                     | Supergen, Inc.                                     |   |                |
|                    |                       | WO 98 54156 A1  | 12/03/1998                     | Rhone-Poulenc Rorer                                |   |                |
|                    |                       | DE 199 24 401 A1  | 11/30/2000                     | BI Pharma KG                                       |   |                |
|                    |                       | DE 100 42 696 A1  | 03/14/2002                     | BI Pharma KG                                       |   |                |
|                    |                       | WO 97 41844 A1  | 11/13/1997                     | Alcon Labs., Inc.                                  |   |                |

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |   |    |   |                          |                           |
|--|---|----|---|--------------------------|---------------------------|
| Substitute for form 1449B/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(Use as many sheets as necessary) |   |    |   | <b>Complete if Known</b> |                           |
|  |   |    |   | Application Number       | 10/830,147                |
|  |   |    |   | Filing Date              | 04/22/2004                |
|  |   |    |   | First Named Inventor     | Martin Friedrich STEFANIC |
|  |   |    |   | Art Unit                 | 1614                      |
|  |   |    |   | Examiner Name            |                           |
| Sheet  | 3 | of | 3 | Attorney Docket Number   | 1/1464US                  |

| NON PATENT LITERATURE DOCUMENTS |                       |   |                |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials*              | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |
|                                 |                       | JONES, H. E. ET AL; "Effect of an EGF-R Selective Tyrosine Kinase Inhibitor and an Anti-Androgen on LNCaP Cells: Identification of Divergent Growth Regulatory Pathways"; The Prostate 49:38-47 (2001) XP008022176  |                |
|                                 |                       | Abstract for DE10233500   |                |
|                                 |                       | Abstract for DE10042696   |                |
|                                 |                       | Abstract for DE19924401   |                |
|                                 |                       |   |                |
|                                 |                       |   |                |
|                                 |                       |   |                |
|                                 |                       |   |                |
|                                 |                       |   |                |
|                                 |                       |   |                |
|                                 |                       |   |                |
|                                 |                       |   |                |
|                                 |                       |   |                |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.